These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
728 related articles for article (PubMed ID: 26265119)
21. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting. Shirley M Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534 [TBL] [Abstract][Full Text] [Related]
22. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting. Balu S; Buchner D; Craver C; Gayle J Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990 [TBL] [Abstract][Full Text] [Related]
23. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron. Coluzzi F; Mattia C Future Oncol; 2016 Aug; 12(16):1865-76. PubMed ID: 27184113 [TBL] [Abstract][Full Text] [Related]
24. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Aapro M; Fabi A; Nolè F; Medici M; Steger G; Bachmann C; Roncoroni S; Roila F Ann Oncol; 2010 May; 21(5):1083-8. PubMed ID: 20080830 [TBL] [Abstract][Full Text] [Related]
25. Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron. Vacirca J; Caruana D; Calcanes G; Mosier M; Boccia R; McBride A Future Oncol; 2018 Jun; 14(14):1387-1396. PubMed ID: 29421926 [TBL] [Abstract][Full Text] [Related]
26. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial. van der Vorst MJDL; Toffoli EC; Beusink M; van Linde ME; van Voorthuizen T; Brouwer S; van Zweeden AA; Vrijaldenhoven S; Berends JC; Berkhof J; Verheul HMW Oncologist; 2021 Jan; 26(1):e173-e181. PubMed ID: 32735029 [TBL] [Abstract][Full Text] [Related]
27. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S; Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083 [TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Yu Z; Liu W; Wang L; Liang H; Huang Y; Si X; Zhang H; Liu D; Zhang H Support Care Cancer; 2009 Jan; 17(1):99-102. PubMed ID: 18825421 [TBL] [Abstract][Full Text] [Related]
29. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy. Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177 [TBL] [Abstract][Full Text] [Related]
30. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369 [TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Suzuki K; Yamanaka T; Hashimoto H; Shimada Y; Arata K; Matsui R; Goto K; Takiguchi T; Ohyanagi F; Kogure Y; Nogami N; Nakao M; Takeda K; Azuma K; Nagase S; Hayashi T; Fujiwara K; Shimada T; Seki N; Yamamoto N Ann Oncol; 2016 Aug; 27(8):1601-6. PubMed ID: 27358385 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). Karthaus M; Tibor C; Lorusso V; Singh-Arora R; Filippov A; Rizzi G; Borroni ME; Rossi G; Grunberg SM Support Care Cancer; 2015 Oct; 23(10):2917-23. PubMed ID: 25724407 [TBL] [Abstract][Full Text] [Related]
33. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Schwartzberg L; Barbour SY; Morrow GR; Ballinari G; Thorn MD; Cox D Support Care Cancer; 2014 Feb; 22(2):469-77. PubMed ID: 24141698 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer. Murakami M; Hashimoto H; Yamaguchi K; Yamaguchi I; Senba S; Siraishi T Support Care Cancer; 2014 Apr; 22(4):905-9. PubMed ID: 24240649 [TBL] [Abstract][Full Text] [Related]
35. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Rubenstein EB Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC). Hesketh PJ; Morrow G; Komorowski AW; Ahmed R; Cox D Support Care Cancer; 2012 Oct; 20(10):2633-7. PubMed ID: 22733373 [TBL] [Abstract][Full Text] [Related]
37. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center. Gamble M; Carroll E; Wright GC; Glode AE J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140 [TBL] [Abstract][Full Text] [Related]
39. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551 [TBL] [Abstract][Full Text] [Related]
40. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Armbruster SD; Fellman BM; Jhingran A; Eifel PJ; Klopp AH; Coleman RL; Ramondetta LM; Frumovitz M Support Care Cancer; 2021 Jan; 29(1):213-222. PubMed ID: 32338316 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]